For decades, C-peptide was considered nothing more than a byproduct of insulin production — a fragment split off when the body converts proinsulin into active insulin. Because it didn’t appear to influence blood sugar directly, clinicians largely ignored it. But over the last 20 years, research has flipped that narrative: C-peptide is now recognized as a […]
In the last five years, GLP-1 receptor agonists (GLP-1 RAs) have gone from being niche diabetes drugs to headline-grabbing weight-loss therapies. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not only reshaping how we treat type 2 diabetes, but also redefining the entire conversation around obesity and metabolic health. The impact is enormous:→ More […]
Non-alcoholic fatty liver disease (NAFLD) and obesity are two of the fastest-growing health problems worldwide. In the U.S. alone, more than 100 million adults are estimated to have fatty liver, with many progressing toward non-alcoholic steatohepatitis (NASH), a serious condition that can lead to cirrhosis and liver failure. At the same time, nearly 42% of American […]
The last decade has seen an explosion of new therapies for obesity and metabolic disease, with GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) dominating headlines and prescriptions. These medications have redefined what’s possible for medical weight management, delivering double-digit weight loss percentages that rival surgical outcomes. But the race is far from […]
When it comes to restoring hormone balance, supporting fertility, or aiding recovery after anabolic steroid use, two compounds are frequently compared: Gonadorelin and HCG (human chorionic gonadotropin). Both play essential roles in regulating the hypothalamic–pituitary–gonadal (HPG) axis, yet they operate at different points along the pathway. Gonadorelin is a synthetic version of GnRH (gonadotropin-releasing hormone), the […]